Ontology highlight
ABSTRACT:
SUBMITTER: Mato AR
PROVIDER: S-EPMC7552812 | biostudies-literature | 2018 Nov
REPOSITORIES: biostudies-literature
Mato Anthony R AR Roeker Lindsey E LE Allan John N JN Pagel John M JM Brander Danielle M DM Hill Brian T BT Cheson Bruce D BD Furman Richard R RR Lamanna Nicole N Tam Constantine S CS Handunnetti Sasanka S Jacobs Ryan R Lansigan Frederick F Bhavsar Erica E Barr Paul M PM Shadman Mazyar M Skarbnik Alan P AP Goy Andre A Beach Douglas F DF Svoboda Jakub J Pu Jeffrey J JJ Sehgal Alison R AR Zent Clive S CS Tuncer Hande H HH Schuster Stephen J SJ Pickens Peter V PV Shah Nirav N NN Rhodes Joanna J Ujjani Chaitra S CS Nabhan Chadi C
American journal of hematology 20180926 11
Ibrutinib demonstrated superior response rates and survival for treatment-naïve chronic lymphocytic leukemia (CLL) patients in a pivotal study that excluded patients younger than 65 (<65) and/or with chromosome 17p13 deletion (del[17p13]). We examined outcomes and toxicities of CLL patients who would have been excluded from the pivotal study, specifically <65 and/or those with del[17p13]. This multicenter, retrospective cohort study examined CLL patients treated with front-line ibrutinib at 20 c ...[more]